Biomarker-Driven Lung Cancer

The KRYSTAL-12 trial of adagrasib showed positive results for progression-free survival and tumor response in KRAS G12C-mutated non-small cell lung cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Misako Nagasaka, MD, PhD, asked participants how they would approach therapy for a patient with metastatic non–small cell lung cancer when biomarker testing is not yet completed. This is the second of 2 articles based on this event.

During a Targeted Oncology™ Case-Based Roundtable™ event, Misako Nagasaka, MD, PhD, held a discussion on the use of biomarker testing in patients with advanced non–small cell lung cancer. This is the first of 2 articles based on this event.

The FDA has granted the supplemental new drug application of repotrectinib priority review.

The combination of avutometinib and sotorasib received FDA fast track designation for the treatment of KRAS G12C-mutant non–small cell lung cancer.

In a presentation during the 41st Annual Chemotherapy Foundation Symposium Innovative Cancer Therapy for Tomorrow conference, Jessica Lin, MD, discussed the landscape of targeted therapies in driver mutations in non–small cell lung cancer.

Following a patient death in the phase 2 IOV-LUN-202 trial, the FDA has issued a clinical hold.

Two PD-L1 tests, SP263 and 22C3, show high agreement & effectively identify patients with early-stage non–small cell lung cancer who are likely to benefit from adjuvant atezolizumab.

The FDA did not fully approve sotorasib for the treatment of patients with KRAS G12C-mutated non–small cell lung cancer.

Anlotinib, a novel multi-targeting tyrosine kinase inhibitor, and icotinib, a first-generation EGFR TKI, demonstrated efficacy and tolerability in the first line for the treatment of patients with EGFR-mutated advanced non–small cell lung cancer.

In an interview with Targeted Oncology, Edward B. Garon, MD, MS, discussed the ever-changing treatment landscape for EGFR-mutated lung cancer, as well as the unmet needs and potential next steps for research in this space.

During a Targeted Oncology™ Case-Based Roundtable™ event, Devika Das, MD, discussed the role of KRAS inhibitors and the outcome of the KRYSTAL-1 trial in patients with non–small cell lung cancer. This is the first of 2 articles based on this event.

Liza C. Villaruz, MD, discusses what research in the EGFR-positive lung cancer space has recently caught the attention of experts.

Repotrectinib is now an FDA-approved option for patients with ROS1- positive advanced non-small cell lung cancer.

In an interview with Targeted Oncology, Joshua Sabari, MD, discussed the rationale of studying LY3537982 in the LOXO-RAS-20001 trial and next steps for the evaluation of the agent.

During a Targeted Oncology™ Community Case Forum event in collaboration with the Tennessee Oncology Practice Society, Jason Porter, MD, reviewed the CodeBreaK 100 and CodeBreaK 200 trials of sotorasib for patients with KRAS-mutant non–small cell lung cancer.

Datopotamab deruxtecan delivered promising responses in patients with heavily pretreated non–small cell lung cancer with actionable genomic alterations.

Combining amivantamab, carboplatin, and pemetrexed in patients with non–small cell lung cancer and an EGFR exon 20 insertion led to improved progression-free survival, overall response rate, duration of response, and a trend toward overall survival benefit vs chemotherapy alone in the randomized phase 3 PAPILLON study.

During a Targeted Oncology™ Case-Based Roundtable™ event, Millie S. Das, MD, and participants discussed considerations for managing toxicities of amivantamab and mobocertinib for patients with EGFR exon 20 insertion–positive non–small cell lung cancer.

Longer follow-up data from the KRYSTAL-7 trial support the initiation of a phase 3 trial evaluating concurrent adagrasib with pembrolizumab in treatment-naïve patients with KRASG12C-mutated non–small cell lung cancer and PD-L1 ≥50%.

The phase 3 ALINA study of alectinib is the first to show an improvement in its primary end point of disease-free survival among patients with early-stage resected ALK-positive non–small cell lung cancer.

Major pathological response and pathological complete response data from the phase 3 RATIONALE 315 study in NSCLC will be presented at the European Society for Medical Oncology Congress 2023.

This regulatory decision follows the recent FDA approval of encorafenib plus binimetinib for adult patients with metastatic non-small cell lung cancer harboring a BRAF V600E mutation.